NCT06507189 Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)
| NCT ID | NCT06507189 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Florida Institute for Human and Machine Cognition |
| Condition | Aging |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-01-27 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 250 participants in total. It began in 2025-01-27 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments that compromise healthspan and quality of life. Exercise is a multipotent treatment with promise to mitigate most aging hallmarks, but there is substantial variability in exercisƒe responsiveness. Combining endurance and resistance training in alignment with public health guidelines will be used to better understand variable exercise responsiveness in older adults with the ultimate goal of improving each older adult's capacity to attain the many health benefits of exercise.
Eligibility Criteria
Inclusion Criteria: 1. Male or female aged 60 or above 2. Free of chronic disease 3. No structured exercise program (2 or more bouts/wk) within previous 12 months 4. Cognitively capable of providing informed consent Exclusion Criteria: 1. Neuromuscular or musculoskeletal disorder that would limit ability to perform the exercise and/or testing bouts 2. Cardiopulmonary disorders or reduced breathing capacity 3. Metabolic diseases including markers of liver disease (ALT \> 52 U/l) and type 2 diabetes (HbA1C = or \> 6.5, fasting blood glucose = or \> 126 mg/dl) 4. Any other disease or disorder that would influence exercise response (e.g., chronic kidney disease, dementia, current cancer diagnosis or within 2 yr remission, cerebrovascular disease) 5. Any current infectious disease 6. Life expectancy \< 1 year 7. Insulin sensitizing/blood glucose lowering agents such as metformin or metabolic weight loss agents (e.g. GLP-1 agonists) 8. High dose statin (dose equivalent of 40 mg/d or higher simvastatin) 9. Lidocaine allergy 10. Regular tobacco use and/or vaping 11. Excessive alcohol consumption (3 drinks/d or 7 drinks/wk for females; 4 drinks/d or 14 drinks/wk for males) 12. BMI 35.0 kg/m2 or higher 13. Unable to commit to \~6 months required to complete the study
Contact & Investigator
Marcas Bamman
PRINCIPAL INVESTIGATOR
Florida Institute for Human and Machine Cognition
Frequently Asked Questions
Who can join the NCT06507189 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06507189 currently recruiting?
Yes, NCT06507189 is actively recruiting participants. Contact the research team at ctuggle@ihmc.org for enrollment information.
Where is the NCT06507189 trial being conducted?
This trial is being conducted at Pensacola, United States, Oklahoma City, United States.
Who is sponsoring the NCT06507189 clinical trial?
NCT06507189 is sponsored by Florida Institute for Human and Machine Cognition. The principal investigator is Marcas Bamman at Florida Institute for Human and Machine Cognition. The trial plans to enroll 250 participants.